Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled trial of BI 764198 in focal segmental glomerulosclerosis
CTR20230035Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing BI 764198 arm with Placebo arm (2 arms). Primary endpoint: Proportion of patients with ≥25% reduction in 24-hour urine protein-creatinine ratio from baseline at Week 12. Started Jan 2023; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on CTR20230035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230035.